A statistically but not clinically significant rise in PSA in the non high-risk subgroup only was observed," Dr. Pastuszak said," and there were more prostate cancer recurrences in the control group than the testosterone replacement therapy group," he added.
"This is a retrospective study. We need prospective clinical trials with longer follow-up because prostate cancer is such a slow-growing malignancy," Dr. Pastuszak told Medscape Medical News. "Ultimately, there are questions remaining about the impact of testosterone on prostate cancer in humans; we need to understand that relationship at the molecular level."
American Urological Association (AUA) 2012 Annual Scientific Meeting: Abstract 1488. Presented May 22, 2012.